CJC-1295 no DAC Review | Buy CJC-1295 no DAC

lotilabs blog banner

CJC-1295 no DAC Review | Buy CJC-1295 no DAC

Please Read our Disclaimer

CJC-1295 without DAC is synthetic analog of Growth Hormone Releasing Factor (GRF) also known as Growth Hormone Releasing Hormone (GHRH). It is a Growth Hormone Secretagogue (GHS) which means it stimulates the secretion of growth hormone.

CJC-1295 no DAC on the other hand is composed of 30 amino acid chains with a molecular weight of 3,3367.2g/mol. Its main mechanism of action mimics the action of GRF/GHRH and stimulate the production of GH. Due to its ability to conjugate or bind with albumin, it counteracts the proteolytic effect of Dipeptidyl Amino Peptidase-IV (DPP-IV) and has a longer half-life.

Modified GRF1-29

Growth Hormone Releasing Hormone (GHRH) or GRF has a total of 44 amino acid chain in its structure, however, studies have confirmed that the first 29 amino acids have the same activity and effect as that of the full chain. This fragment has been known as GRF 1-29.

The main problem with GRF1-29 is its very fast half-life, which lasts only for less than seven minutes. This is due to the proteolytic action of the DPP-IV enzyme. Aside from that, DPP-IV is also involved in other biological processes like apoptosis or programmed cell death, signal transduction, and immune system regulation.

A number of modified GRF1-29 has been developed recently but animal testing in pigs and rats have shown that CJC-1295 is the most stable in stimulating the release of GH. This is why CJC-1295 without dac is also referred to as modified GRF1-29

CJC-1295 without DAC and GHRP/Ipamorelin

CJC-1295 is often combined with Drug Affinity Complex (DAC) and other growth hormone secretagogues such as Growth Hormone Releasing Peptides (GHRP) which includes GHRP-2, GHRP-6, and Ipamorelin.

The difference between these combinations to that with CJC-1295 without DAC and GHRP or Ipamorelin is the increase in GH release and very long half-life.

Effects of CJC-1295 without DAC

Studies and animal experiments have found CJC-1295 without DAC to demonstrate the following effects;

            Increase Protein Synthesis. CJC-1295 without DAC’s ability to resist enzyme degradation and stimulate the release of Growth Hormone leads to a cascade of processes that leads to increase protein synthesis in animal test subjects.

            Decrease Adipose Tissue. Adipose tissue or fat are broken down in a process known as lipolysis. CJC 1295 without DAC has shown to accelerate this process thus its ability to decrease body fat.

            Accelerate Wound Healing. The process of wound healing involves several steps and involves a number of proteins. The ability of CJC-1295 without DAC to increase protein synthesis help in this process. Rats given CJC-1295 have shown faster wound healing time compared to those that didn’t receive any.

            Higher Bone Density. CJC-1295 without DAC through animal testing has demonstrated to increase bone mineral matter per square inch. It also contributed to the decrease in possibility of fractures, breaks, and other bone related issues.

Where to Buy CJC-1295

USA-made CJC-1295 can be purchased from Loti Labs. CJC-1295 from Loti Labs are tested through HPLC and Mass Spectrometry to ensure quality, purity, and the integrity of any research or study conducted using it. It is commonly sold in 5mg vials and is available in lyophilized powder form.

References:

  1. Alba, M. et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology, Endocrinology and Metabolism.
  2. Jette, L. et al. (2005). hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: Identification of CJC-1295 as a long lasting GRF analog. Endocrinology.
  3. Benquet, C. et al. (2004). (CJC-1295 (DAC-GRF), a long acting GRF analog, enhances pulsatile GH secretion, increases IGF-I levels, and restores linear growth. Program of the 86th Annual Meeting of the Endocrine Society, New Orleans, LA, p 491 (Abstract P3-109).

Share this post

Disclaimer-lotilabs-banner